Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P. R. China.
Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P. R. China
Br J Ophthalmol. 2022 Nov;106(11):1581-1586. doi: 10.1136/bjophthalmol-2021-319118. Epub 2021 May 26.
To explore the risk factors for ophthalmic artery (OA) stenosis and occlusion after intra-arterial chemotherapy (IAC) with selective ophthalmic artery catheterisation (OAC) in the treatment of retinoblastoma.
Retrospective, single centre case-control study.
The study was conducted including consecutive patients with unilateral or bilateral intraocular retinoblastoma undergoing IAC between June 2016 and June 2019 with a follow-up time of 4 years. Main outcomes are rate of IAC-induced OA occlusion and OA diameter.
346 attempted OAC infusions were successful. The total incidence of OA occlusion was 15.89%. The occlusion and control groups were similar in patients' age, sex and disease stage. Median OA diameter was 0.49 mm in those with OA occlusion, and 0.66 mm in those without occlusion. In the occlusion group, the OA diameter difference was significantly larger between the first IAC and the final IAC (0.22mm vs 0.12mm, p=0.001). In both groups, the median number of IAC treatments was 3. Multivariate Cox regression models included initial OA diameter (OR: 0.005, p=0.001), ratio of OA orifice diameter differences between first and last IAC to the initial OA orifice diameter (OR: 4.661, p=0.003), and number of IAC (OR: 1.538, p=0.042) as clinical features significantly associated with OA occlusion.
The OA diameter at first IAC treatment, the ratio of OA orifice diameter differences between first and last IAC to the initial OA orifice diameter and total number of IAC treatments may be three main clinical predictors for OA occlusion after IAC for retinoblastoma.
探讨选择性眼动脉插管(OAC)介入治疗视网膜母细胞瘤(RB)中眼动脉(OA)狭窄和闭塞的危险因素。
回顾性、单中心病例对照研究。
该研究纳入了 2016 年 6 月至 2019 年 6 月期间接受 IAC 治疗的单侧或双侧眼内 RB 连续患者,随访时间为 4 年。主要结局为 IAC 引起的 OA 闭塞率和 OA 直径。
346 次 OAC 输注均成功。OA 闭塞总发生率为 15.89%。闭塞组和对照组在患者年龄、性别和疾病分期方面无差异。OA 闭塞组的 OA 直径中位数为 0.49mm,无 OA 闭塞组为 0.66mm。在闭塞组中,首次 IAC 和末次 IAC 的 OA 直径差异显著(0.22mm 比 0.12mm,p=0.001)。两组 IAC 治疗中位数均为 3 次。多变量 Cox 回归模型包括初始 OA 直径(OR:0.005,p=0.001)、首次和末次 IAC 之间 OA 口直径差异与初始 OA 口直径的比值(OR:4.661,p=0.003)和 IAC 数量(OR:1.538,p=0.042)作为与 OA 闭塞显著相关的临床特征。
首次 IAC 治疗时的 OA 直径、首次和末次 IAC 之间 OA 口直径差异与初始 OA 口直径的比值以及 IAC 治疗总数可能是预测 RB 患者 IAC 后 OA 闭塞的三个主要临床预测因素。